You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

mTOR kinase inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer Trial in Miami (AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor +

Not yet recruiting
  • Breast Cancer
  • +3 more
  • Miami, Florida
    University of Miami
Apr 12, 2023

Advanced Malignant Tumor, Metastatic Malignant Tumor, Recurrent Malignant Tumor Trial in Houston (Everolimus, Laboratory

Recruiting
  • Advanced Malignant Neoplasm
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

Brain and CNS Tumors Trial in Memphis (GDC-0084, radiation therapy)

Completed
  • Brain and Central Nervous System Tumors
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Jan 13, 2023

Multiple Myeloma, DLBCL, Glioblastoma Multiforme Trial in Worldwide (CC-223)

Completed
Has Results
  • Multiple Myeloma
  • +6 more
  • Los Angeles, California
  • +15 more
Dec 9, 2022

Bile Acids in Acute Insulin Resistance

Recruiting
  • PI3K Gene Mutation
  • +4 more
  • Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
  • New York, New York
    Columbia University Medical Center
Oct 6, 2022

Pancreatic Ductal Adenocarcinoma Trial (combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • combination therapy with no MEKi
  • +3 more
  • (no location specified)
Nov 29, 2022

Pulmonary Hypertension Trial in United States (ABI-009, nab-rapamycin, albumin-bound rapamycin)

Active, not recruiting
  • Pulmonary Hypertension
  • ABI-009, nab-rapamycin, albumin-bound rapamycin
  • Tucson, Arizona
  • +5 more
Aug 22, 2022

Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase

Recruiting
  • Liver Transplant
  • PVHA or TACE
  • Shanghai, Shanghai, China
    The value of tumor feeding vessels deprivation combined with tyr
Nov 26, 2022

Cushing Disease Trial (Fimepinostat)

Not yet recruiting
  • Cushing Disease
  • (no location specified)
Jul 31, 2023

Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 Trial in United States (Selumetinib, Sirolimus)

Active, not recruiting
  • Malignant Peripheral Nerve Sheath Tumors
  • Neurofibromatosis 1
  • Washington, District of Columbia
  • +4 more
Apr 1, 2022

Advanced Solid Tumor, Metastatic Solid Tumor Trial (PEP07)

Not yet recruiting
  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • (no location specified)
Aug 1, 2023

Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)

Recruiting
  • Liver Neoplasms
  • Tislelizumab plus tyrosine kinase inhibitor
  • Beijing, Beijing, China
    302 Hospital
Sep 22, 2023

Cyclin-dependent Kinase Inhibitor 2A on Labor-related Signals

Not yet recruiting
  • Preterm Labor
    • (no location specified)
    May 9, 2023

    Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer Trial in Boston (Palbociclib, Gedatolisib)

    Recruiting
    • Lung Cancer Squamous Cell
    • +3 more
    • Boston, Massachusetts
    • +2 more
    Jan 9, 2023

    Acute Myeloid Leukemia, Lymphoma, Mantle-Cell Trial (PEP07)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • Lymphoma, Mantle-Cell
    • (no location specified)
    Dec 22, 2022

    Acute Lymphoblastic Leukemia Trial in Ann Arbor (Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy)

    Recruiting
    • Acute Lymphoblastic Leukemia
    • Ann Arbor, Michigan
      University of Michigan Rogel Cancer Center
    Nov 28, 2022

    Sjogren's Syndrome Trial run by the National Institute of Dental and Craniofacial Research (NIDCR) (tofacitinib, Placebo)

    Recruiting
    • Sjogren's Syndrome
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Nov 24, 2022

    CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

    Recruiting
    • CML
    • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
    • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
      FUNDALEU
    Jun 29, 2023

    Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)

    Recruiting
    • Neurofibromatosis 1
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    Breast Cancer Trial in Guangzhou (Take probiotics)

    Recruiting
    • Breast Cancer
    • Take probiotics
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Mar 6, 2023

    Kinase Inhibitor Targeted Therapies

    Not yet recruiting
    • Blood Concentrations of Nine Anti-cancer Drugs : Axitinib, Olaparib, regorafénib, Cabozantinib, Niraparib, Talazoparib, Palbociclib, Abemaciclib, Tucatinib
    • Measurement of drug concentrations
    • Rennes, France
    • +2 more
    Nov 7, 2022

    Gastrointestinal Stromal Tumors (GISTs) Trial in Seoul (Imatinib Mesylate)

    Completed
    • Gastrointestinal Stromal Tumors (GISTs)
    • Imatinib Mesylate
    • Seoul, Korea, Republic of
      Asan Medical Center
    Dec 30, 2022

    Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma Trial in Saint Louis (device, drug, procedure)

    Recruiting
    • Pancreas Cancer
    • +2 more
    • MR-guided stereotactic body radiation therapy
    • +3 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jan 29, 2023

    SCLC, Small Cell Cancer, Advanced Solid Tumor Trial run by the NCI (Lurbinectedin, Berzosertib)

    Recruiting
    • SCLC
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

    Not yet recruiting
    • Lung Cancer
    • Non Small Cell Lung Cancer
    • Amivantamab 1050mg
    • +2 more
    • Aurora, Colorado
    • +2 more
    Apr 25, 2023